Completed PHASE3 INTERVENTIONAL 2-arm NCT04259164

Anti-inflammatory Effects Glycopyrronium

Evaluation of the Anti-inflammatory Effects of Glycopyrronium Added to Indacaterol/Mometasone on the Allergen-induced Late Asthmatic Response

Sponsor: Novartis

Conditions Allergic Asthma Asthma

Interventions QMF149 QVM149

Updated 7 times since 2020 Last updated: Jan 11, 2023 Started: Sep 10, 2020 Primary completion: Dec 29, 2022 Completion: Dec 29, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Allergic Asthma and Asthma, this trial is completed. The trial is conducted by Novartis and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2023 — Jul 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Dec 2022 — Feb 2023 [monthly]

Active Not Recruiting PHASE3

Status: Unknown Status → Active Not Recruiting
Mar 2022 — Dec 2022 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jan 2021 — Mar 2022 [monthly]

Not Yet Recruiting PHASE3
Mar 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
University Medical Center Groningen

Data source: University Medical Center Groningen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands